Can you take Fezolinetant with Peginterferon beta-1a?

Peginterferon beta-1a has a moderate potential interaction with Autoimmune Disorders.

Autoimmune disorders of multiple target organs including idiopathic thrombocytopenia, hyper- and hypothyroidism, and autoimmune hepatitis have been reported with interferon beta. If patients develop a new autoimmune disorder, consider stopping therapy with this agent. Care and close monitoring is recommended when prescribing this agent to patients at risk of developing an autoimmune disorder.

Peginterferon beta-1a has a moderate potential interaction with Bone Marrow Depression/Low Blood Counts.

Interferon beta can cause decreased peripheral blood counts in all cell lines, including rare instances of pancytopenia and severe thrombocytopenia. It is recommended to monitor patients for infections, bleeding, and symptoms of anemia. Monitor complete blood cell counts, differential white blood cell counts, and platelet counts during treatment. Close monitoring is recommended when prescribing this agent to patients at risk, in particular to patients with myelosuppression.

Peginterferon beta-1a has a moderate potential interaction with Depression.

Depression, suicidal ideation, and suicide have been reported in patients receiving peginterferon beta. Patients should be monitored for any evidence of depression or other psychiatric symptoms. Patients should be advised to report any signs or symptoms of depression, or other changes in mood or behavior. In severe cases, therapy should be stopped immediately and psychiatric intervention should be instituted.

Peginterferon beta-1a has a moderate potential interaction with Dermatitis, Drug-Induced.

Injection site reactions, including injection site necrosis, can occur with the use of subcutaneous interferon beta. Caution should be exercised when prescribing this agent and the decisions to discontinue therapy following necrosis at a single injection site should be based on the extent of the necrosis. For patients who continue therapy after injection site necrosis has occurred, it is recommended to avoid administration of this agent near the affected area until it is fully healed and if multiple lesions occur, discontinue therapy until healing occurs.

Peginterferon beta-1a has a moderate potential interaction with Heart Disease.

Congestive heart failure, cardiomyopathy, and cardiomyopathy with congestive heart failure occur in patients receiving interferon beta. It is recommended to monitor patients with significant cardiac disease for worsening of their cardiac condition during initiation and continuation of treatment.

Peginterferon beta-1a has a moderate potential interaction with Hemolytic Anemia.

Cases of thrombotic microangiopathy (TMA), including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, some fatal, have been reported with interferon beta products. Discontinue therapy if clinical symptoms and laboratory findings are consistent with TMA, and manage as clinically indicated. Care should be taken when prescribing this agent to patients at risk of endothelial injury.

Fezolinetant has a major potential interaction with Liver Disease.

Fezolinetant is contraindicated in patients with known cirrhosis and has not been studied in patients with Child-Pugh C hepatic impairment. Drug exposure is increased in patients with Child-Pugh A or B hepatic impairment. Fezolinetant may increase serum transaminase levels and drug-induced liver injury has been reported within 40 days of initiation. Assess liver function at baseline, monthly for the first 3 months, then at 6 and 9 months of therapy, or if symptoms of liver injury occur. Do not initiate therapy if ALT, AST, or total bilirubin is 2 times the upper limit of normal or greater. Treatment discontinuation may be required if transaminase elevations occur.

Peginterferon beta-1a has a major potential interaction with Liver Disease.

Severe hepatic injury, including hepatitis, autoimmune hepatitis, cases of hepatic failure and asymptomatic transient increases in the concentrations of serum transaminases, have been reported in patients treated with beta interferons. In some cases, these events have occurred in the presence of other drugs that have been associated with hepatic injury. The potential risk of these agents used in combination with known hepatotoxic drugs or other products (e.g., alcohol) should be considered before starting therapy, or before starting hepatotoxic drugs. Patients should be monitored for signs of hepatic injury, including the regular monitoring of liver function tests, and discontinuation of therapy should be considered if serum transaminase levels significantly increase or if hepatic injury occurs.

Peginterferon beta-1a has a moderate potential interaction with Pancytopenia.

Interferon beta can cause decreased peripheral blood counts in all cell lines, including rare instances of pancytopenia and severe thrombocytopenia. It is recommended to monitor patients for infections, bleeding, and symptoms of anemia. Monitor complete blood cell counts, differential white blood cell counts, and platelet counts during treatment. Close monitoring is recommended when prescribing this agent to patients at risk, in particular to patients with myelosuppression.

Fezolinetant has a major potential interaction with Renal Dysfunction.

Fezolinetant is contraindicated in patients with severe renal impairment or end-stage renal disease. Avoid use in patients with an estimated GFR less than 30 mL/min/1.73 m2.

Peginterferon beta-1a has a moderate potential interaction with Renal Dysfunction.

Pharmacokinetic studies have shown that renal impairment can increase the Cmax of Peginterferon beta-1a. Caution should be taken when prescribing this agent to these patients. It is recommended to monitor renal function, and to monitor for adverse reactions due to increased drug exposure in patients with severe renal impairment. Clinical monitoring of renal function is recommended.

Peginterferon beta-1a has a moderate potential interaction with Seizures.

The use of peginterferon beta-1a may cause seizures. Exercise caution when prescribing this agent to patients with a history of seizure disorders. Close monitoring is recommended.

Peginterferon beta-1a has a moderate potential interaction with Vasculitis.

Cases of thrombotic microangiopathy (TMA), including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, some fatal, have been reported with interferon beta products. Discontinue therapy if clinical symptoms and laboratory findings are consistent with TMA, and manage as clinically indicated. Care should be taken when prescribing this agent to patients at risk of endothelial injury.